Search - tctmd.com

Displaying 21 - 40 of 249

Sort: Relevancy | Date

Presentation TCT 2019

Welcome, Introductions, and Session Goals

Presenter: Roxana Mehran

September 28, 2019

Presentation TCT 2019

Why Do We Need a Dedicated DES for Diabetes?: Introducing the Abluminus Concept

Presenter: Roxana Mehran

September 28, 2019

Presentation TCT 2019

Case #3 Resolution: How Did We Treat This Patient? What Might We Have Done Differently?

Presenter: Roxana Mehran

September 27, 2019

Presentation TCT 2019

Case #3 Introduction: A Case in Which We Might Consider Bridging

Presenter: Roxana Mehran

September 27, 2019

Presentation TCT 2019

Drop ASA/ REDUCE Duration

Presenter: Roxana Mehran

September 27, 2019

Presentation TCT 2019

Welcome and Introductions

Presenter: Roxana Mehran

September 27, 2019

Presentation TCT 2019

Final Words

Presenter: Roxana Mehran

September 26, 2019

Presentation TCT 2019

Welcome and Introductions

Presenter: Roxana Mehran

September 26, 2019

Presentation TCT 2019

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Presenter: Roxana Mehran

September 26, 2019

Presentation CIT 2019

The landscape of Ongoing HBR Clinical Trials & an Introduction to HBR-ARC Initiative

Presenter: Roxana Mehran

March 28, 2019

Presentation OPCI 2019

Optimal Duration of Antiplatelet Therapy – Does IV Imaging Make A Difference?

Presenter: Roxana Mehran

March 09, 2019

Presentation JIM 2019

Consider Low Dose RIVAROXABAN + SAPT

Presenter: Roxana Mehran

February 15, 2019

Presentation TCT 2018

Diversity in the Interventional Workplace: Current Challenges and Opportunities

Presenter: Wayne B. Batchelor, Aaron Horne, Jr., Roxana Mehran

September 24, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Otavio Berwanger, Peter Juni, Sanjay Kaul, Roxana Mehran, E. Magnus Ohman, Stuart J. Pocock, Giulio Stefanini

September 23, 2018

Presentation TCT 2018

Stent Trials in High Bleeding Risk Patients: What is the Level of Evidence We Need?

Presenter: Peter Juni, Robert W. Yeh, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Consensus: Considerations In The High Bleeding Risk Patient Requiring PCI And Oral Anticoagulant Therapy

Presenter: George D. Dangas, Giuseppe Tarantini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Case #2 Conclusion: How Did I Actually Treat This Patient?

Presenter: George D. Dangas, Giuseppe Tarantini, Steven R. Bailey, Giovanni Esposito, Juan F. Granada, Roxana Mehran, Francesco Saia

September 23, 2018

Presentation TCT 2018

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Case #2 Introduction: A Patient With Chronic CAD At High Bleeding Risk Requiring PCI

Presenter: George D. Dangas, Giuseppe Tarantini, Steven R. Bailey, Giovanni Esposito, Juan F. Granada, Roxana Mehran, Francesco Saia

September 23, 2018

Presentation TCT 2018

Case #1 Conclusion: How Did I Actually Treat This Patient?

Presenter: George D. Dangas, Giuseppe Tarantini, Steven R. Bailey, Giovanni Esposito, Juan F. Granada, Roxana Mehran, Francesco Saia

September 23, 2018

Advertisement

Welcome, Introductions, and Session Goals

Why Do We Need a Dedicated DES for Diabetes?: Introducing the Abluminus Concept

Case #3 Resolution: How Did We Treat This Patient? What Might We Have Done Differently?

Case #3 Introduction: A Case in Which We Might Consider Bridging

Drop ASA/ REDUCE Duration

Welcome and Introductions

Final Words

Welcome and Introductions

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

The landscape of Ongoing HBR Clinical Trials & an Introduction to HBR-ARC Initiative

Optimal Duration of Antiplatelet Therapy – Does IV Imaging Make A Difference?

Consider Low Dose RIVAROXABAN + SAPT

Diversity in the Interventional Workplace: Current Challenges and Opportunities

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Stent Trials in High Bleeding Risk Patients: What is the Level of Evidence We Need?

Consensus: Considerations In The High Bleeding Risk Patient Requiring PCI And Oral Anticoagulant Therapy

Case #2 Conclusion: How Did I Actually Treat This Patient?

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Case #2 Introduction: A Patient With Chronic CAD At High Bleeding Risk Requiring PCI

Case #1 Conclusion: How Did I Actually Treat This Patient?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content